Filtered By:
Specialty: Endocrinology
Drug: Actos

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 28 results found since Jan 2013.

Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial
Pioglitazone, an antidiabetic drug, also exerts several cardiometabolic benefits including antioxidant, anti-inflammatory, antihypertensive, vasoprotective and hypolipidemic effects. These pioglitazone-related benefits have been observed in different patient populations such as those with prediabetes, non-alcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). With regard to cardiovascular (CV) morbidity and mortality, there is conflicting evidence.Recently, the Insulin Resistance Intervention after Stroke (IRIS) trial reported a significant pioglitazone-induced decrease in CV morbidity in patients with insulin ...
Source: Journal of Diabetes and Its Complications - September 17, 2016 Category: Endocrinology Authors: Niki Katsiki, Dimitri P Mikhailidis Source Type: research

Pioglitazone Slows Progression to Type 2 Diabetes: More IRIS DataPioglitazone Slows Progression to Type 2 Diabetes: More IRIS Data
New and previously reported data from the IRIS trial prompt discussion of reevaluating the role of now-generic pioglitazone in the treatment and prevention of diabetes and stroke. Medscape Medical News
Source: Medscape Diabetes Headlines - June 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
Source: Journal of Diabetes - June 7, 2016 Category: Endocrinology Authors: Silvio E. Inzucchi, Karen L. Furie Tags: Commentary Source Type: research

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

VIDEO: Post-stroke pioglitazone modestly protective against secondary vascular events
LOS ANGELES – Nondiabetic, insulin-resistant patients who started pioglitazone within 6 months of an ischemic stroke or transient ischemic attack had almost a 3% absolute risk reduction in secondary...
Source: Clinical Endocrinology News - February 19, 2016 Category: Endocrinology Source Type: news

Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - January 8, 2016 Category: Endocrinology Authors: E. Erdmann, S. Harding, H. Lam, A. Perez Tags: ORIGINAL ARTICLE Source Type: research

10‐Year Observational Follow‐Up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution due to limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - November 23, 2015 Category: Endocrinology Authors: Erland Erdmann, Sarah Harding, Hung Lam, Alfonso Perez Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
ConclusionThere were no differences in overall cardiovascular risks among several add‐on second‐line oral antidiabetic agents; however, glinide plus metformin and α‐glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 1, 2015 Category: Endocrinology Authors: Y.‐C. Chang, L.‐M. Chuang, J.‐W. Lin, S.‐T. Chen, M.‐S. Lai, C.‐H. Chang Tags: Research Article Source Type: research

Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia
Conclusions Because of the higher prevalence of abnormal cognition in aged outpatients with diabetes found in primary care practice and significant associations with serum albumin, uric acid, renal function, retinopathy and antidiabetic drugs, there is a need for early diagnosis and strategies against dementia.
Source: Diabetology International - November 9, 2014 Category: Endocrinology Source Type: research

Observational follow‐up of the PROactive study: a 6‐year update†
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: E. Erdmann, E. Song, R. Spanheimer, A.‐R. van Troostenburg de Bruyn, A. Perez Tags: ORIGINAL ARTICLE Source Type: research

Observational follow‐up of the PROactive Study: a 6‐year update
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - July 22, 2013 Category: Endocrinology Authors: Erland Erdmann, Eric Song, Robert Spanheimer, Anne‐Ruth van Troostenburg de Bruyn, Alfonso Perez Tags: Original Paper Source Type: research